Harvard Bioscience Q1 revenue $20.8M, gross margin 59%; reaffirms FY guidance

HARVARD BIOSCIENCE INC

2026-Q1 EPS reported -$0.77 vs consensus -$0.63 ▼ miss (-21.8%)

Revenue $20.8M (down 5% YoY from $21.8M); net loss $(3.4)M vs $(50.3)M including $48M impairment.
Gross margin 59% (vs 56% prior year); driven by higher-margin NPI mix (MeshMEA, BTX, SoHo).
Adjusted EBITDA $0.8M flat YoY; cash used in ops $(0.7)M vs $3.0M in Q1 2025.
Reaffirms full-year 2026 guidance; manufacturing consolidation on track for efficiencies.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001171843-26-003270

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.